[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY29823A1 - Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones - Google Patents

Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones

Info

Publication number
UY29823A1
UY29823A1 UY29823A UY29823A UY29823A1 UY 29823 A1 UY29823 A1 UY 29823A1 UY 29823 A UY29823 A UY 29823A UY 29823 A UY29823 A UY 29823A UY 29823 A1 UY29823 A1 UY 29823A1
Authority
UY
Uruguay
Prior art keywords
preparation
compounds
piridine
imidazol
chlorine
Prior art date
Application number
UY29823A
Other languages
English (en)
Inventor
Dider Rotticci
Per I Arvidsson
Peter Soderman
Erwan Arzel
Helena Gybrck
Rein Tobias
Jeremy Burrows
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY29823A1 publication Critical patent/UY29823A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula I como una base libre o una sal farmacéuticamente aceptable, solvato o solvato de una sal de los mismos, un proceso para su preparación y a nuevos productos intermedios allí utilizados, formulaciones farmacéuticas que contienen dichos compuestos terapéuticamente activos y al uso de dichos de dichos compuestos activos en terapia. Los compuestos son útiles para el tratamiento de alzheimer, taupatías, enfermedades neurodegenerativas, trastornos bipolares, esquizofrenia, diabetes, pérdida de cabello, como anticonceptivos orales, y para trastornos óseos.
UY29823A 2005-10-03 2006-09-29 Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones UY29823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502173 2005-10-03

Publications (1)

Publication Number Publication Date
UY29823A1 true UY29823A1 (es) 2007-05-31

Family

ID=37906402

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29823A UY29823A1 (es) 2005-10-03 2006-09-29 Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones

Country Status (16)

Country Link
US (1) US20080255106A1 (es)
EP (1) EP1934217A4 (es)
JP (1) JP2009510162A (es)
KR (1) KR20080057334A (es)
CN (1) CN101321754A (es)
AR (1) AR057525A1 (es)
AU (1) AU2006297889A1 (es)
BR (1) BRPI0616663A2 (es)
CA (1) CA2624869A1 (es)
IL (1) IL189945A0 (es)
NO (1) NO20082054L (es)
SA (1) SA06270365B1 (es)
TW (1) TW200800984A (es)
UY (1) UY29823A1 (es)
WO (1) WO2007040439A1 (es)
ZA (1) ZA200802637B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
WO2007083978A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
AU2008233319A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[ 4,5-B]pyridine-7-carboxamides 704
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
ES2573412T3 (es) 2010-09-10 2016-06-07 Shionogi & Co., Ltd. Derivado de imidazol de heteroanillo fusionado que tiene efecto de AMPK (activacion de proteina cinasa activada por monofosfato de adenosina)
US20170209488A1 (en) 2014-07-17 2017-07-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CN107151235B (zh) * 2016-03-04 2019-12-13 上海市计划生育科学研究所 噻二唑烷二酮基gsk3抑制剂在调节精子运动能力中的用途
ES2896938T3 (es) * 2016-11-28 2022-02-28 Bristol Myers Squibb Co Inhibidores de GSK-3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL338575A1 (en) * 1997-08-05 2000-11-06 Pfizer Prod Inc 4-aminopyrrole(3,2-d)pyrimidines as antagonists of neuropeptide y receptor
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
MXPA04007697A (es) * 2002-02-06 2004-11-10 Vertex Pharma Compuestos de heteroarilo utiles como inhibidores de gsk-3.
DE60318826T2 (de) * 2002-03-27 2009-01-22 Nycomed Gmbh Alkoxypyridinderivate
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
KR100791252B1 (ko) * 2003-01-23 2008-01-03 크리스탈지노믹스(주) 글리코겐 합성효소 키나아제 3β 활성 억제제, 이의제조방법 및 이를 유효성분으로 함유하는 약학 조성물
EP1675854B1 (en) * 2003-10-01 2008-06-25 Nycomed GmbH Imidazopyridine-derivatives as inductible no-synthase inhibitors
NZ546435A (en) * 2003-10-01 2009-08-28 Altana Pharma Ag Imidazopyridine-derivatives as inducible NO-synthase inhibitors
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
WO2007083978A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same

Also Published As

Publication number Publication date
BRPI0616663A2 (pt) 2011-06-28
AR057525A1 (es) 2007-12-05
TW200800984A (en) 2008-01-01
AU2006297889A1 (en) 2007-04-12
WO2007040439A1 (en) 2007-04-12
IL189945A0 (en) 2008-08-07
SA06270365B1 (ar) 2009-12-22
US20080255106A1 (en) 2008-10-16
KR20080057334A (ko) 2008-06-24
EP1934217A4 (en) 2010-08-04
CN101321754A (zh) 2008-12-10
JP2009510162A (ja) 2009-03-12
EP1934217A1 (en) 2008-06-25
CA2624869A1 (en) 2007-04-12
ZA200802637B (en) 2008-12-31
NO20082054L (no) 2008-06-02

Similar Documents

Publication Publication Date Title
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
ECSP088405A (es) Nuevos derivados de pirimidina y su uso en terapia, así como el uso de derivados de pirimidina en la fabricación de un medicamento para la prevención y/o tratamiento de la enfermedad de alzheimer
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
PA8547701A1 (es) Nucleosidos 4 substituidos.
SE0200979D0 (sv) New compounds
PA8591701A1 (es) Derivados de pirrolopirimidina
GT200400116A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
UY28510A1 (es) Compuestos quimicos
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
CO6361928A2 (es) Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1
ATE381535T1 (de) Phenethanolaminderivate
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
ECSP077185A (es) Derivados de piridina
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
SE0100569D0 (sv) New compounds
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
ATE386725T1 (de) Heterocyclylverbindungen
UY27593A1 (es) Nuevos compuestos
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160920